Osteoid osteoma: Difference between revisions

Jump to navigation Jump to search
Line 66: Line 66:


==Pathophysiology==
==Pathophysiology==
*The exact etiology of osteoid osteoma is unknown.
*The exact etiology of osteoid osteoma is unknown.<ref name="pmid24830123">{{cite journal |vauthors=Athwal P, Stock H |title=Osteoid osteoma: a pictorial review |journal=Conn Med |volume=78 |issue=4 |pages=233–5 |year=2014 |pmid=24830123 |doi= |url=}}</ref>
*Osteoid osteoma arises from the osteoblasts.
*Osteoid osteoma arises from the osteoblasts.
*Osteoid osteoma consists of radially oriented trabeculae of surrounding reactive bone, indicating an increased pressure in the vascular nidus.   
*Osteoid osteoma consists of radially oriented trabeculae of surrounding reactive bone, indicating an increased pressure in the vascular nidus.   
*This arrangement of the bony trabeculae is due to the stresses placed on them.  
*This arrangement of the bony trabeculae is due to the stresses placed on them.  
*This increased pressure is due to vasodilatation and edema is which stimulate intraosseous nerve endings, generating pain.
*This increased pressure is due to vasodilatation and edema is which stimulate intraosseous nerve endings, generating pain.<ref name="pmid9504688">{{cite journal |vauthors=O'Connell JX, Nanthakumar SS, Nielsen GP, Rosenberg AE |title=Osteoid osteoma: the uniquely innervated bone tumor |journal=Mod. Pathol. |volume=11 |issue=2 |pages=175–80 |year=1998 |pmid=9504688 |doi= |url=}}</ref>
*In addiition, the pain is also attributed to increased local concentration of prostaglandin E2, COX1 & 2 expression;  and increased number and size of unmyelinated nerve fibers within the nidus.
*In addiition, the pain is also attributed to increased local concentration of prostaglandin E2, COX1 & 2 expression;  and increased number and size of unmyelinated nerve fibers within the nidus.
*Osteoid osteomas are usually cortical lesions but they can occur anywhere within the bone including medullary, subperiosteal (most common in talus), and intracapsular area.
*Osteoid osteomas are usually cortical lesions but they can occur anywhere within the bone including medullary, subperiosteal (most common in talus), and intracapsular area.
*More than 50 percent of osteoid osteomas occur in lower extremity of long bones.<ref name="pmid3849059">{{cite journal |vauthors=Torg JS, Loughran T, Pavlov H, Schwamm H, Gregg J, Sherman M, Balduini FC |title=Osteoid osteoma. Distant, periarticular, and subarticular lesions as a cause of knee pain |journal=Sports Med |volume=2 |issue=4 |pages=296–304 |year=1985 |pmid=3849059 |doi= |url=}}</ref><ref>{{cite book | last = Peabody | first = Terrance | title = Orthopaedic oncology : primary and metastatic tumors of the skeletal system | publisher = Springer | location = Cham | year = 2014 | isbn = 9783319073224 }}</ref>
*It most commonly affects  the metadiaphysis of the femur and tibia.
*About 20 percent of osteoid osteomas occur in the posterior elements of the spine.
==Genetics==
*The structural chromosomal alterations involving 22q13.1 in osteoid osteoma may affect critical genes involved in the regulation of cell proliferation, such as the YWHAH gene.<ref name="pmid11172903">{{cite journal| author=Baruffi MR, Volpon JB, Neto JB, Casartelli C| title=Osteoid osteomas with chromosome alterations involving 22q. | journal=Cancer Genet Cytogenet | year= 2001 | volume= 124 | issue= 2 | pages= 127-31 | pmid=11172903 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11172903  }} </ref>
*YWHAH gene codes for a 14-3-3 family members of dimeric phosphoserine-binding proteins that participate in signal transduction and checkpoint control pathways.
*Their primary function is to inhibit apoptosis.
*Another gene mapped in this region is PDGFB that codes for a platelet-derived growth factor, a beta polypeptide (simian sarcoma viral [v-sis] oncogene homolog), a potent mitogen for cells of mesenchymal origin and involved in the transformation process.


==Causes==
==Causes==

Revision as of 16:36, 18 December 2018


For patient information click here
For more information about osteoma that is not associated with osteoid osteoma, see osteoma Template:Osteoid osteoma Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Maria Fernanda Villarreal, M.D. [2]

Synonyms and keywords: Osteoma osteoid; OO; Osteoid osteomas


Overview

Historical Perspective

  • In 1930, Dr. Bergstrand, a German physician, first described osteoid osteoma in 1930.[1]
  • In 1935, Dr.Henry Jaffe, an American pathologist first described osteoid osteoma as a benign bone tumor.[2]
  • In 1953, Dr. Jaffe coined the term nidus, which was described as the “core”, referring to the tumor itself and is composed of bone at various stages of maturity within a highly vascular connective tissue stroma.[3]
  • In 1954, Dahlin and Johnson added the term giant osteoid osteomas.[4]
  • In 1966, Dr.Edeiken classifed osteoid osteomas into three types.[2]

Classification

  • Osteoid Osteoma can be classified based on location and imaging findings.

Anatomical Classification

Type of osteoid osteoma Characteristics
Intracortical Dense sclerosis around the nidus
Periosteal Periosteal reaction
Cancellous (medullary) Produces very little reactive bone
Subarticular Simulates arthritis as it produces synovial reactions


Enneking (MSTS) Staging System

  • The Enneking surgical staging system (also known as the MSTS system) for benign musculoskeletal tumors based on radiographic characteristics of the tumor host margin.[7]
  • It is widely accepted and routinely used classification.


Stages Description
1 Latent: Well demarcated borders
2 Active: Indistinct borders
3 Aggressive: Indistinct borders

Pathophysiology

  • The exact etiology of osteoid osteoma is unknown.[8]
  • Osteoid osteoma arises from the osteoblasts.
  • Osteoid osteoma consists of radially oriented trabeculae of surrounding reactive bone, indicating an increased pressure in the vascular nidus.
  • This arrangement of the bony trabeculae is due to the stresses placed on them.
  • This increased pressure is due to vasodilatation and edema is which stimulate intraosseous nerve endings, generating pain.[9]
  • In addiition, the pain is also attributed to increased local concentration of prostaglandin E2, COX1 & 2 expression; and increased number and size of unmyelinated nerve fibers within the nidus.
  • Osteoid osteomas are usually cortical lesions but they can occur anywhere within the bone including medullary, subperiosteal (most common in talus), and intracapsular area.
  • More than 50 percent of osteoid osteomas occur in lower extremity of long bones.[2][10]
  • It most commonly affects the metadiaphysis of the femur and tibia.
  • About 20 percent of osteoid osteomas occur in the posterior elements of the spine.

Genetics

  • The structural chromosomal alterations involving 22q13.1 in osteoid osteoma may affect critical genes involved in the regulation of cell proliferation, such as the YWHAH gene.[11]
  • YWHAH gene codes for a 14-3-3 family members of dimeric phosphoserine-binding proteins that participate in signal transduction and checkpoint control pathways.
  • Their primary function is to inhibit apoptosis.
  • Another gene mapped in this region is PDGFB that codes for a platelet-derived growth factor, a beta polypeptide (simian sarcoma viral [v-sis] oncogene homolog), a potent mitogen for cells of mesenchymal origin and involved in the transformation process.

Causes

Disease name] may be caused by [cause1], [cause2], or [cause3].

OR

Common causes of [disease] include [cause1], [cause2], and [cause3].

OR

The most common cause of [disease name] is [cause 1]. Less common causes of [disease name] include [cause 2], [cause 3], and [cause 4].

OR

The cause of [disease name] has not been identified. To review risk factors for the development of [disease name], click here.

Differentiating ((Page name)) from Other Diseases

[Disease name] must be differentiated from other diseases that cause [clinical feature 1], [clinical feature 2], and [clinical feature 3], such as [differential dx1], [differential dx2], and [differential dx3].

OR

[Disease name] must be differentiated from [[differential dx1], [differential dx2], and [differential dx3].

Epidemiology and Demographics

The incidence/prevalence of [disease name] is approximately [number range] per 100,000 individuals worldwide.

OR

In [year], the incidence/prevalence of [disease name] was estimated to be [number range] cases per 100,000 individuals worldwide.

OR

In [year], the incidence of [disease name] is approximately [number range] per 100,000 individuals with a case-fatality rate of [number range]%.


Patients of all age groups may develop [disease name].

OR

The incidence of [disease name] increases with age; the median age at diagnosis is [#] years.

OR

[Disease name] commonly affects individuals younger than/older than [number of years] years of age.

OR

[Chronic disease name] is usually first diagnosed among [age group].

OR

[Acute disease name] commonly affects [age group].


There is no racial predilection to [disease name].

OR

[Disease name] usually affects individuals of the [race 1] race. [Race 2] individuals are less likely to develop [disease name].


[Disease name] affects men and women equally.

OR

[Gender 1] are more commonly affected by [disease name] than [gender 2]. The [gender 1] to [gender 2] ratio is approximately [number > 1] to 1.


The majority of [disease name] cases are reported in [geographical region].

OR

[Disease name] is a common/rare disease that tends to affect [patient population 1] and [patient population 2].

Risk Factors

There are no established risk factors for [disease name].

OR

The most potent risk factor in the development of [disease name] is [risk factor 1]. Other risk factors include [risk factor 2], [risk factor 3], and [risk factor 4].

OR

Common risk factors in the development of [disease name] include [risk factor 1], [risk factor 2], [risk factor 3], and [risk factor 4].

OR

Common risk factors in the development of [disease name] may be occupational, environmental, genetic, and viral.

Screening

There is insufficient evidence to recommend routine screening for [disease/malignancy].

OR

According to the [guideline name], screening for [disease name] is not recommended.

OR

According to the [guideline name], screening for [disease name] by [test 1] is recommended every [duration] among patients with [condition 1], [condition 2], and [condition 3].

Natural History, Complications, and Prognosis

If left untreated, [#]% of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3].

OR

Common complications of [disease name] include [complication 1], [complication 2], and [complication 3].

OR

Prognosis is generally excellent/good/poor, and the 1/5/10-year mortality/survival rate of patients with [disease name] is approximately [#]%.

Diagnosis

Diagnostic Study of Choice

The diagnosis of [disease name] is made when at least [number] of the following [number] diagnostic criteria are met: [criterion 1], [criterion 2], [criterion 3], and [criterion 4].

OR

The diagnosis of [disease name] is based on the [criteria name] criteria, which include [criterion 1], [criterion 2], and [criterion 3].

OR

The diagnosis of [disease name] is based on the [definition name] definition, which includes [criterion 1], [criterion 2], and [criterion 3].

OR

There are no established criteria for the diagnosis of [disease name].

History and Symptoms

The majority of patients with [disease name] are asymptomatic.

OR

The hallmark of [disease name] is [finding]. A positive history of [finding 1] and [finding 2] is suggestive of [disease name]. The most common symptoms of [disease name] include [symptom 1], [symptom 2], and [symptom 3]. Common symptoms of [disease] include [symptom 1], [symptom 2], and [symptom 3]. Less common symptoms of [disease name] include [symptom 1], [symptom 2], and [symptom 3].

Physical Examination

Patients with [disease name] usually appear [general appearance]. Physical examination of patients with [disease name] is usually remarkable for [finding 1], [finding 2], and [finding 3].

OR

Common physical examination findings of [disease name] include [finding 1], [finding 2], and [finding 3].

OR

The presence of [finding(s)] on physical examination is diagnostic of [disease name].

OR

The presence of [finding(s)] on physical examination is highly suggestive of [disease name].

Laboratory Findings

An elevated/reduced concentration of serum/blood/urinary/CSF/other [lab test] is diagnostic of [disease name].

OR

Laboratory findings consistent with the diagnosis of [disease name] include [abnormal test 1], [abnormal test 2], and [abnormal test 3].

OR

[Test] is usually normal among patients with [disease name].

OR

Some patients with [disease name] may have elevated/reduced concentration of [test], which is usually suggestive of [progression/complication].

OR

There are no diagnostic laboratory findings associated with [disease name].

Electrocardiogram

There are no ECG findings associated with [disease name].

OR

An ECG may be helpful in the diagnosis of [disease name]. Findings on an ECG suggestive of/diagnostic of [disease name] include [finding 1], [finding 2], and [finding 3].

X-ray

There are no x-ray findings associated with [disease name].

OR

An x-ray may be helpful in the diagnosis of [disease name]. Findings on an x-ray suggestive of/diagnostic of [disease name] include [finding 1], [finding 2], and [finding 3].

OR

There are no x-ray findings associated with [disease name]. However, an x-ray may be helpful in the diagnosis of complications of [disease name], which include [complication 1], [complication 2], and [complication 3].

Echocardiography or Ultrasound

There are no echocardiography/ultrasound findings associated with [disease name].

OR

Echocardiography/ultrasound may be helpful in the diagnosis of [disease name]. Findings on an echocardiography/ultrasound suggestive of/diagnostic of [disease name] include [finding 1], [finding 2], and [finding 3].

OR

There are no echocardiography/ultrasound findings associated with [disease name]. However, an echocardiography/ultrasound may be helpful in the diagnosis of complications of [disease name], which include [complication 1], [complication 2], and [complication 3].

CT scan

There are no CT scan findings associated with [disease name].

OR

[Location] CT scan may be helpful in the diagnosis of [disease name]. Findings on CT scan suggestive of/diagnostic of [disease name] include [finding 1], [finding 2], and [finding 3].

OR

There are no CT scan findings associated with [disease name]. However, a CT scan may be helpful in the diagnosis of complications of [disease name], which include [complication 1], [complication 2], and [complication 3].

MRI

There are no MRI findings associated with [disease name].

OR

[Location] MRI may be helpful in the diagnosis of [disease name]. Findings on MRI suggestive of/diagnostic of [disease name] include [finding 1], [finding 2], and [finding 3].

OR

There are no MRI findings associated with [disease name]. However, a MRI may be helpful in the diagnosis of complications of [disease name], which include [complication 1], [complication 2], and [complication 3].

Other Imaging Findings

There are no other imaging findings associated with [disease name].

OR

[Imaging modality] may be helpful in the diagnosis of [disease name]. Findings on an [imaging modality] suggestive of/diagnostic of [disease name] include [finding 1], [finding 2], and [finding 3].

Other Diagnostic Studies

There are no other diagnostic studies associated with [disease name].

OR

[Diagnostic study] may be helpful in the diagnosis of [disease name]. Findings suggestive of/diagnostic of [disease name] include [finding 1], [finding 2], and [finding 3].

OR

Other diagnostic studies for [disease name] include [diagnostic study 1], which demonstrates [finding 1], [finding 2], and [finding 3], and [diagnostic study 2], which demonstrates [finding 1], [finding 2], and [finding 3].

Treatment

Medical Therapy

There is no treatment for [disease name]; the mainstay of therapy is supportive care.

OR

Supportive therapy for [disease name] includes [therapy 1], [therapy 2], and [therapy 3].

OR

The majority of cases of [disease name] are self-limited and require only supportive care.

OR

[Disease name] is a medical emergency and requires prompt treatment.

OR

The mainstay of treatment for [disease name] is [therapy].

OR   The optimal therapy for [malignancy name] depends on the stage at diagnosis.

OR

[Therapy] is recommended among all patients who develop [disease name].

OR

Pharmacologic medical therapy is recommended among patients with [disease subclass 1], [disease subclass 2], and [disease subclass 3].

OR

Pharmacologic medical therapies for [disease name] include (either) [therapy 1], [therapy 2], and/or [therapy 3].

OR

Empiric therapy for [disease name] depends on [disease factor 1] and [disease factor 2].

OR

Patients with [disease subclass 1] are treated with [therapy 1], whereas patients with [disease subclass 2] are treated with [therapy 2].

Surgery

Surgical intervention is not recommended for the management of [disease name].

OR

Surgery is not the first-line treatment option for patients with [disease name]. Surgery is usually reserved for patients with either [indication 1], [indication 2], and [indication 3]

OR

The mainstay of treatment for [disease name] is medical therapy. Surgery is usually reserved for patients with either [indication 1], [indication 2], and/or [indication 3].

OR

The feasibility of surgery depends on the stage of [malignancy] at diagnosis.

OR

Surgery is the mainstay of treatment for [disease or malignancy].

Primary Prevention

There are no established measures for the primary prevention of [disease name].

OR

There are no available vaccines against [disease name].

OR

Effective measures for the primary prevention of [disease name] include [measure1], [measure2], and [measure3].

OR

[Vaccine name] vaccine is recommended for [patient population] to prevent [disease name]. Other primary prevention strategies include [strategy 1], [strategy 2], and [strategy 3].

Secondary Prevention

There are no established measures for the secondary prevention of [disease name].

OR

Effective measures for the secondary prevention of [disease name] include [strategy 1], [strategy 2], and [strategy 3].

References

  1. Karandikar S, Thakur G, Tijare M, Shreenivas K, Agrawal K (2011). "Osteoid osteoma of mandible". BMJ Case Rep. 2011. doi:10.1136/bcr.10.2011.4886. PMC 3233922. PMID 22669768.
  2. 2.0 2.1 2.2 Torg JS, Loughran T, Pavlov H, Schwamm H, Gregg J, Sherman M, Balduini FC (1985). "Osteoid osteoma. Distant, periarticular, and subarticular lesions as a cause of knee pain". Sports Med. 2 (4): 296–304. PMID 3849059.
  3. Chai JW, Hong SH, Choi JY, Koh YH, Lee JW, Choi JA; et al. (2010). "Radiologic diagnosis of osteoid osteoma: from simple to challenging findings". Radiographics. 30 (3): 737–49. doi:10.1148/rg.303095120. PMID 20462991.
  4. DAHLIN DC, JOHNSON EW (1954). "Giant osteoid osteoma". J Bone Joint Surg Am. 36-A (3): 559–72. PMID 13163088.
  5. Morton KS, Vassar PS, Knickerbocker WJ (1975). "Osteoid osteoma and osteoblastoma: reclassification of 43 cases using Schajowicz's classification". Can J Surg. 18 (2): 148–52. PMID 1116053.
  6. Hakim DN, Pelly T, Kulendran M, Caris JA (2015). "Benign tumours of the bone: A review". J Bone Oncol. 4 (2): 37–41. doi:10.1016/j.jbo.2015.02.001. PMC 4620948. PMID 26579486.
  7. Jawad MU, Scully SP (2010). "In brief: classifications in brief: enneking classification: benign and malignant tumors of the musculoskeletal system". Clin Orthop Relat Res. 468 (7): 2000–2. doi:10.1007/s11999-010-1315-7. PMC 2882012. PMID 20333492.
  8. Athwal P, Stock H (2014). "Osteoid osteoma: a pictorial review". Conn Med. 78 (4): 233–5. PMID 24830123.
  9. O'Connell JX, Nanthakumar SS, Nielsen GP, Rosenberg AE (1998). "Osteoid osteoma: the uniquely innervated bone tumor". Mod. Pathol. 11 (2): 175–80. PMID 9504688.
  10. Peabody, Terrance (2014). Orthopaedic oncology : primary and metastatic tumors of the skeletal system. Cham: Springer. ISBN 9783319073224.
  11. Baruffi MR, Volpon JB, Neto JB, Casartelli C (2001). "Osteoid osteomas with chromosome alterations involving 22q". Cancer Genet Cytogenet. 124 (2): 127–31. PMID 11172903.


Template:WikiDoc Sources